Kalevi Pyörälà - Concepedia

Author

Kalevi Pyörälà

Kuopio University Hospital

Also Known As

B. Zethelius, E. Lim, I. Graham, K PYORALA, K Pyorala, K Pyöräla, K Pyörälä, K Pyōrālā, K. PYORALA, K. PYÖRÄLA

301

Publications

52.7K

Citations

H-Index

174

Concepts

All Affiliations

Kuopio University Hospital University of Eastern Finland Social Insurance Institution University of Helsinki University of Turku

About

Kalevi Pyörälà is an author at Kuopio University Hospital specializing in medicine, cardiovascular disease, and public health.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	50	93	20.8K
2	Public Health	46	72	21.7K
3	Health Sciences	15	17	1.3K
4	Education	1	1	14
5	Allergy	1	1	59

Kalevi Pyörälà

183

Publications

47.9K

Citations

H-Index

Page 1

	Year	Citations
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Anders Olsson, John J.V. McMurray, G Thorgeirsson, The Lancet Cardiovascular DiseaseHealth PolicyHyperlipidemiaDyslipidemiaPreventive Cardiology	1994	8.5K
Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction Steven M. Haffner, Seppo Lehto, Tapani Rönnemaa, New England Journal of Medicine	1998	7K
Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Ian Graham, Dan Atar, Knut Borch‐Johnsen, European Journal of Cardiovascular Prevention & Rehabilitation HypertensionAdult Cardiac SurgeryPreventive CardiologyCoronary Artery DiseaseInvited Experts	2007	1.7K
Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) Kalevi Pyörälà, Terje R. Pedersen, John Kjekshus, Diabetes Care	1997	1.6K
Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria K. Borch‐Johnsen, Andrew Neil, Beverley Balkau, The Lancet Metabolic SyndromeDiabetes ManagementDiabetes EpidemiologyHealth PolicyGlobal Health	1999	1.3K
EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE Daniel De Backer, K. Borch‐Johnsen, Carlos Brotons, Rational Pharmacotherapy in Cardiology	2005	1.3K
Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention1European Society of Cardiology, European Atherosclerosis Society, European Society of Hypertension, International Society of Behavioural Medicine, European Society of General Practice/Family Medicine, European Heart Network.1,2Published simultaneously in the European Heart Journal 1998;19:1434–1503 and the Journal of Hypertension (Summary only) 1998;16(10).2 David Wood, Guy De Backer, Ian D. Graham, Atherosclerosis	1998	1.3K
Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries Kornelia Kotseva, David Wood, Guy De Backer, The Lancet Non-pharmacological InterventionHypertensionPreventive MedicineIii SurveysCardiovascular Disease	2009	834
EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries Kornelia Kotseva, David Wood, Guy De Backer, European Journal of Cardiovascular Prevention & Rehabilitation	2009	806
Relationship of Glucose Tolerance and Plasma Insulin to the Incidence of Coronary Heart Disease: Results from Two Population Studies in Finland Kalevi Pyörälà Diabetes Care	1979	783

Page 1